Bryn Mawr Capital Management LLC Sells 5,491 Shares of Amgen Inc. (NASDAQ:AMGN)

Bryn Mawr Capital Management LLC lowered its position in Amgen Inc. (NASDAQ:AMGN) by 28.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,662 shares of the medical research company’s stock after selling 5,491 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Amgen were worth $3,935,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. OFI Invest Asset Management bought a new position in Amgen in the third quarter valued at $26,000. Briaud Financial Planning Inc bought a new position in Amgen in the third quarter valued at $26,000. BOK Financial Private Wealth Inc. bought a new position in Amgen in the fourth quarter valued at $29,000. Providence Capital Advisors LLC bought a new position in Amgen in the third quarter valued at $30,000. Finally, Planned Solutions Inc. bought a new position in Amgen in the fourth quarter valued at $30,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN traded up $0.60 during trading hours on Friday, reaching $269.98. The company had a trading volume of 2,436,947 shares, compared to its average volume of 2,822,655. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The firm has a market cap of $144.81 billion, a price-to-earnings ratio of 21.62, a PEG ratio of 2.54 and a beta of 0.58. The firm’s 50 day moving average price is $275.10 and its 200-day moving average price is $281.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter in the previous year, the firm posted $4.09 EPS. The company’s revenue for the quarter was up 19.8% compared to the same quarter last year. On average, analysts forecast that Amgen Inc. will post 19.43 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.33%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is currently 72.06%.

Analysts Set New Price Targets

A number of research firms recently commented on AMGN. UBS Group reduced their target price on Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. TD Cowen reduced their price objective on Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $324.00 to $318.00 in a report on Wednesday, February 7th. Raymond James initiated coverage on shares of Amgen in a report on Thursday, March 28th. They set a “market perform” rating for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $329.00 target price on shares of Amgen in a report on Wednesday, April 3rd. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.